Original Article

You have full text access to this OnlineOpen article

Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly†

  1. Steven E. Schild M.D.1,‡,*,
  2. Philip J. Stella M.D.2,
  3. Burke J. Brooks M.D.3,
  4. Sumithra Mandrekar Ph.D.1,
  5. James A. Bonner M.D.4,
  6. William L. McGinnis M.D.5,
  7. James A. Mailliard M.D.6,
  8. James E. Krook M.D.7,
  9. Richard L. Deming M.D.5,
  10. Alex A. Adjei M.D.1,
  11. Aminah Jatoi M.D.1,
  12. James R. Jett M.D.1

Article first published online: 25 APR 2005

DOI: 10.1002/cncr.21034

Issue

Cancer

Cancer

Volume 103, Issue 11, pages 2349–2354, 1 June 2005

Additional Information

How to Cite

Schild, S. E., Stella, P. J., Brooks, B. J., Mandrekar, S., Bonner, J. A., McGinnis, W. L., Mailliard, J. A., Krook, J. E., Deming, R. L., Adjei, A. A., Jatoi, A. and Jett, J. R. (2005), Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer, 103: 2349–2354. doi: 10.1002/cncr.21034

Author Information

  1. 1

    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  2. 2

    Michigan Cancer Consortium CCOP, Ann Arbor, Michigan

  3. 3

    Ochsner CCOP, New Orleans, Louisiana

  4. 4

    Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama

  5. 5

    Iowa Oncology Research Association CCOP, Des Moines, Iowa

  6. 6

    Missouri Valley Cancer Consortium CCOP, Omaha, Nebraska

  7. 7

    Duluth CCOP, Duluth, Minnesota

  1. ‡

    Fax: (480) 301-7687

*Department of Radiation Oncology, Mayo Clinic, Desk R, 13400 E. Shea Boulevard, Scottsdale, AZ 85259

  1. †

    Additional participating institutions include the following: Duluth CCOP, Duluth, MN (Daniel A. Nikcevich, M.D.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA (Martin Wiesenfeld, M.D.); Meritcare Hospital CCOP, Fargo, ND (Ralph Levitt, M.D.); Toledo Community Hospital Oncology Program CCOP, Toledo, OH (Paul L. Schaefer, M.D.); Sioux Community Cancer Consortium, Sioux Falls, SD (Loren K. Tschetter, M.D.); Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair, M.D.); Rapid City Regional Oncology Group, Rapid City, SD (Larry P. Ebbert, M.D.); Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada and Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (Muhammad Salim, M.D.); Scottsdale CCOP, Scottsdale, AZ (Tom R. Fitch, M.D.); Carle Cancer Center CCOP, Urbana, IL (Kendrith M. Rowland, M.D.); Medcenter One Health Systems, Bismarck, ND (Ferdinand Addo, M.D.); Altru Health Systems, Grand Forks, ND (Tudor Dentchev, M.D.); Siouxland Hematology-Oncology Associates, Sioux City, IA (John C. Michalak, M.D.); CentreCare Clinic, St. Cloud, MN (Harold E. Windschitl, M.D.); and Illinois Oncology Research Assn., CCOP, Peoria, IL (John W. Kugler, M.D.).

Publication History

  1. Issue published online: 18 MAY 2005
  2. Article first published online: 25 APR 2005
  3. Manuscript Accepted: 12 JAN 2005
  4. Manuscript Revised: 7 JAN 2005
  5. Manuscript Received: 16 NOV 2004

Funded by

  • North Central Cancer Treatment Group, Mayo Clinic, Public Health Service Grants. Grant Numbers: CA-25224, CA-37404, CA-15083, CA-63826, CA-35269, CA-63849, CA-35113, CA-63848, CA-35416, CA-52352, CA-37417, CA-35103, CA-35448, CA-60276, CA-35195, CA-35101, CA-35103

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (106K)

REFERENCES

  • 1
    Jemal A, Tiwari R, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 8–29.
    Direct Link:
  • 2
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992; 10: 890–895.
  • 3
    National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Available from URL: http://seer.cancer.gov/csr/1975_2000/sections.html [accessed April 1, 2005].
  • 4
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327: 1618–1624.
  • 5
    Auperin A, Arriagada R, Pignon JP, et al. (for the PCI Overview Collaborative Group). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999; 342: 476–484.
  • 6
    Frytak S, Shaw EG, Jett JR, et al. Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. Am J Clin Oncol. 1996; 19: 193–198.
  • 7
    Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999; 17: 2681–2691.
  • 8
    Schild SE, Bonner JA, Shanahan TG, et al. Long term results of a phase III trial comparing once daily radiotherapy or twice daily radiotherapy in limited-stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004; 59: 943–951.
  • 9
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Soc. 1958; 53: 457–481.
  • 10
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 1–39.
  • 11
    Turrisi AT, Kyungmann K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340: 265–271.
  • 12
    Quon H, Shepard FA, Payne DG, et al. The influence of age on the delivery, tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999; 43: 39–45.
  • 13
    Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1996; 14: 821–828.
  • 14
    Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in Intergroup Trial 0096: cisplatin, etoposide and thoracic radiotherapy administered once or twice daily in limited stage small cell lung cancer. Cancer. 2000; 89: 1953–1960.
  • 15
    Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non–small-cell lung cancer in the elderly. J Clin Oncol. 2003; 21: 3201–3206.
  • 16
    Perrone F, Gallo C, Gridille C. Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. J Natl Cancer Inst. 2002; 94: 1029–1030; author reply 1030-1. No abstract available.
  • 17
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999; 91: 66–72.
  • 18
    Jatoi A, Stella P, Hillman S, et al. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (≥65 years of age): a phase II North Central Cancer Treatment Group Study. Am J Clin Oncol. 2003; 26: 441–447.
View Full Article (HTML) Get PDF (106K)